Abstract
Over the last 15 years, the use of various biological therapies has largely improved the way we manage patients with Inflammatory Bowel Diseases (IBDs). Blockade of cytokine synthesis and/or activity is at the forefront of this new era with the success of inhibitors of tumor necrosis factor (TNF)-α. These therapies are however not effective in all IBD patients and efficacy may wane. Moreover, patients treated with anti-TNF-α antibodies can develop severe side-effects and new immune-mediated diseases. Therefore, a new challenge is to elucidate new inflammatory networks in the IBD tissue and develop novel anti-cytokine compounds, which may act in patients who are resistant to or cannot receive anti-TNF-α therapies. In this article we review the available data supporting the pathogenic role of IL-23 and Th17-related cytokines in IBD, and discuss whether and how compounds that control the activity of these cytokines may enter into the therapeutic armamentarium of IBD.
Keywords: IL-23, Th17, IL-17A, IL-21, IBD, Th17-Cytokines, Inflammatory Bowel Diseases, tumor necrosis factor, anti-TNF- antibodies, Crohn's disease, ulcerative colitis, anti-cytokine therapy, interleukin, CD4 cells, interferon, T cells, IL-12, retinoic acid-related orphan receptor, chemokines, polymorphisms, granulocytes, trinitrobenzenesulfonic acid, TNBS-colitis, SCID mice, Bacteroides fragilis, tumours, Neutralization, ABT-874, monoclonal antibody, homeostasis
Current Pharmaceutical Design
Title: Targeting IL-23 and Th17-Cytokines in Inflammatory Bowel Diseases
Volume: 16 Issue: 33
Author(s): Daniela De Nitto, Massimiliano Sarra, Maria Laura Cupi, Francesco Pallone and Giovanni Monteleone
Affiliation:
Keywords: IL-23, Th17, IL-17A, IL-21, IBD, Th17-Cytokines, Inflammatory Bowel Diseases, tumor necrosis factor, anti-TNF- antibodies, Crohn's disease, ulcerative colitis, anti-cytokine therapy, interleukin, CD4 cells, interferon, T cells, IL-12, retinoic acid-related orphan receptor, chemokines, polymorphisms, granulocytes, trinitrobenzenesulfonic acid, TNBS-colitis, SCID mice, Bacteroides fragilis, tumours, Neutralization, ABT-874, monoclonal antibody, homeostasis
Abstract: Over the last 15 years, the use of various biological therapies has largely improved the way we manage patients with Inflammatory Bowel Diseases (IBDs). Blockade of cytokine synthesis and/or activity is at the forefront of this new era with the success of inhibitors of tumor necrosis factor (TNF)-α. These therapies are however not effective in all IBD patients and efficacy may wane. Moreover, patients treated with anti-TNF-α antibodies can develop severe side-effects and new immune-mediated diseases. Therefore, a new challenge is to elucidate new inflammatory networks in the IBD tissue and develop novel anti-cytokine compounds, which may act in patients who are resistant to or cannot receive anti-TNF-α therapies. In this article we review the available data supporting the pathogenic role of IL-23 and Th17-related cytokines in IBD, and discuss whether and how compounds that control the activity of these cytokines may enter into the therapeutic armamentarium of IBD.
Export Options
About this article
Cite this article as:
De Nitto Daniela, Sarra Massimiliano, Laura Cupi Maria, Pallone Francesco and Monteleone Giovanni, Targeting IL-23 and Th17-Cytokines in Inflammatory Bowel Diseases, Current Pharmaceutical Design 2010; 16 (33) . https://dx.doi.org/10.2174/138161210794079164
DOI https://dx.doi.org/10.2174/138161210794079164 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Peripheral Immunity, Immunoaging and Neuroinflammation in Parkinson’s Disease
Current Medicinal Chemistry Peripheral Immune Signatures in Alzheimer Disease
Current Alzheimer Research <i>Larrea tridentata</i> and its Biological Activities
Current Topics in Medicinal Chemistry Immunopathology of Brucella Infection
Recent Patents on Anti-Infective Drug Discovery The Amyloid β-Protein Precursor and Alzheimers Disease. Therapeutic Approaches
Current Medicinal Chemistry - Central Nervous System Agents Preclinical Study of the Pharmacokinetics of p75ECD-Fc, a Novel Human Recombinant Protein for Treatment of Alzheimer’s Disease, in Sprague Dawley Rats
Current Drug Metabolism Cerebral Amyloidoses: Molecular Pathways and Therapeutic Challenges
Current Medicinal Chemistry Neurocysticercosis: The Enigmatic Disease
Central Nervous System Agents in Medicinal Chemistry APP Transgenic Mouse Models and their Use in Drug Discovery to Evaluate Amyloid-β Lowering Therapeutics
CNS & Neurological Disorders - Drug Targets Mitochondrial Calcium Signaling as a Therapeutic Target for Alzheimer’s Disease
Current Alzheimer Research Current Status Of Short Synthetic Peptides As Vaccines
Medicinal Chemistry Anti-inflammatory and Immune Therapy for Alzheimers Disease: Current Status and Future Directions
Current Neuropharmacology Treatment of Central Nervous System Tuberculosis Infections and Neurological Complications of Tuberculosis Treatment
Current Pharmaceutical Design Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety Pathophysiological Roles of Transglutaminase - Catalyzed Reactions in the Pathogenesis of Human Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Virus-Associated Vasculitides: An Update
Current Immunology Reviews (Discontinued) Novel Aβ Immunogens: Is Shorter Better?
Current Alzheimer Research Targeting Mitochondrial Bioenergetics for Alzheimers Prevention and Treatment
Current Pharmaceutical Design Potential Relevance of Melatonin Against Some Infectious Agents: A Review and Assessment of Recent Research
Current Medicinal Chemistry Biochemical Markers in CSF of ALS Patients
Current Medicinal Chemistry